A recent report published by Infinium Global Research on laryngeal cancer therapeutics market provides an in-depth analysis of segments and sub-segments in the global as well as regional laryngeal cancer therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional laryngeal cancer therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global laryngeal cancer therapeutics market. According to the report, the global laryngeal cancer therapeutics market is projected to grow at a CAGR of 7.1% over the forecast period of 2019-2025.

Market Insight

The major players in the global laryngeal cancer therapeutics market are Eli Lilly and Company, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Sanofi S.A., and Merck and Co. Inc. In 2019, Eli Lilly and Company acquired Loxo Oncology, Inc. The acquisition increases the scope of Lilly’s oncology portfolio into precision medicines.

The rising prevalence of laryngeal cancer drives the growth of the laryngeal cancer therapeutics market. In 2019, around 12,410 adults in the United States are diagnosed with laryngeal cancer. The rising number of reimbursement programs contributes to the growth of the laryngeal cancer therapeutics market. The changing lifestyle choices fuel the growth of the laryngeal cancer therapeutics market. The increasing consumption of smoking and alcohol fuel the growth of the laryngeal cancer therapeutics market. The combined influence of tobacco and alcohol contribute to 90 percent of all laryngeal cancers. On the flip side, the availability of alternative treatment options and treatment costs hamper the growth of the laryngeal cancer therapeutics market. Moreover, the growing research and development promote innovations and create numerous opportunities for the growth of the laryngeal cancer therapeutics market.

Geographically, North America is anticipated to be dominant in the laryngeal cancer therapeutics market. North America has a well-established healthcare industry that promotes the growth of the laryngeal cancer therapeutics market. Asia-Pacific region is anticipated to grow in the laryngeal cancer therapeutics market with a healthy CAGR over the forecast period. The rising numbers of smokers fuel the growth of laryngeal cancer cases in the Asia-Pacific region. Europe is growing in the global laryngeal cancer therapeutics market.

Segment Covered

The report on global laryngeal cancer therapeutics market covers segments such as product type and application. On the basis of product type, the sub-markets include biologics, and small molecules. On the basis of application, the sub-markets include hospitals, clinics, and other applications.

Companies Profiled:

The report provides profiles of the companies in the market such as Eli Lilly and Company, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. and Co., Sanofi S.A., and Merck and Co. Inc.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of laryngeal cancer therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.